TSX runs higher on rate cut expectations
Maxcyte NASDAQ:MXCT President and CEO Masoud Maher reported purchasing 75,000 shares of common stock on August 13, 2025, as the stock trades near its 52-week low of $1.26. According to InvestingPro data, the stock has declined nearly 67% over the past six months. The shares were bought in a range of $1.29 to $1.44 per share, for a total transaction value of $102,915.
Following the transaction, Maher directly owns 175,000 shares of Maxcyte.
In other recent news, MaxCyte Inc. reported its second-quarter 2025 earnings, revealing a revenue miss with earnings per share of -$0.12, which was below the expected -$0.10. The company posted revenue of $8.5 million, falling short of the $9.63 million forecast, marking an 11.73% miss. Additionally, MaxCyte reduced its 2025 revenue guidance by $5 million, representing a 14% decrease in its business expectations. Analysts from BTIG downgraded MaxCyte to Neutral, citing ongoing funding challenges for its cell and gene therapy customers. William Blair also downgraded the company to Market Perform due to disappointing performance and reduced guidance. The revised guidance indicates a decline in core organic revenue of 6%-16% for the year, including an approximately 20% drop in the second half. These developments have raised concerns among investors about the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.